SFPT Session 5- What's new in therapeutics?

08:30 • 102 • Off-label use and self-treatment of GLP-1 receptor agonists in individuals with cocaine use disorder: clinical observations and underlying mechanisms > J-L. Jean-Luc Faillie 08:40 • 311 • Serious infections with anti-BCMA/CD3 bispecific antibodies in real life: a retrospective study on the French Pharmacovigilance Database > C. Camille Potey 08:50 • 467 • Daridorexant (QUVIVIQ®): innovative mechanism of action, unusual adverse effects — Focus on sleep paralysis 09:00 • 590 • Medical Nihilism or Medical Hubris? Assessing the accuracy of ChatGPT-4o’s answers on the effectiveness of therapeutic interventions > M. MATHIEU REPIQUET 09:10 • 545 • BleedRisk: a Bayesian online application for predicting Apixaban washout time > J. Jean Escal 09:20 • 121 • Pharmacovigilance analysis of neuropsychiatric disorders in children post Elexacaftor-Tezacaftor-Ivacaftor initiation in cystic fibrosis > D. Diane MERINO